Results showed that there was an exponential increase in the uptake of Cardiol’s nanoparticles in heart failure hearts compared to a control group in a pre-clinical model of non-ischemic heart failure.
Nanoparticles preferentially gathered within cells in fibroblasts, indicating the potential to successfully deliver anti-fibrotic drugs such as cannabidiol to the diseased area of the heart.
READ: Cardiol Therapeutics shares positive new study results supporting lead drug’s ability to protect against heart failure
According to the study, the nanoparticles localized within the diseased hearts in areas known as fibrosis, which is largely responsible for the stiffening and reduced function of the heart muscle.
The data provides new insights into how nanotherapeutics could be used to target the anti-fibrotic properties of cannabidiol to fibrous tissue in a failing heart, according to Dr Arvind Bhimaraj, interim division chief of the Division of Heart Failure and co-director of the Heart Failure Translational Research Laboratory at Houston Methodist DeBakey Heart & Vascular Center, where the study was conducted.
Dr Bhimaraj is a member of the Clinical Steering Committee for Cardiol's planned international clinical trial in acute myocarditis.
"The specific targeting of the fibrotic tissue in the heart offers the potential to utilize drugs more effectively to prevent the progression of heart failure,” Bhimaraj said in a statement.
Data from the study was accepted for presentation at the American College of Cardiology's 69th Annual Scientific Session & Expo together with the World Congress of Cardiology, held virtually at the end of March.
Cardiol is focused on producing pharmaceutical cannabidiol products and developing innovative therapies for heart diseases, including acute myocarditis and other causes of heart failure. Its proprietary nanotechnology is designed to enable the distribution of water-insoluble drugs within the blood circulation, improve pharmacokinetics, and facilitate drug accumulation in the failing heart.
The company is planning an international clinical trial of its flagship drug CardiolRx in acute myocarditis, which is caused by inflammation in heart tissue.
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas